MCID: UTR042
MIFTS: 19

Uterus Leiomyosarcoma malady

Categories: Reproductive diseases, Rare diseases, Cancer diseases, Muscle diseases

Aliases & Classifications for Uterus Leiomyosarcoma

Aliases & Descriptions for Uterus Leiomyosarcoma:

Name: Uterus Leiomyosarcoma 12
Leiomyosarcoma of the Corpus Uteri 56
Leiomyosarcoma of Corpus Uteri 12
Leiomyosarcoma of Uterus 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5289
NCIt 47 C6340
SNOMED-CT 64 447389009
Orphanet 56 ORPHA213625
ICD10 via Orphanet 34 C54.2
UMLS 69 C0280631

Summaries for Uterus Leiomyosarcoma

Disease Ontology : 12 A uterine Corpus sarcoma and leiomyosarcoma and uterine Corpus smooth muscle neoplasm that is located in the smooth muscle of the uterus.

MalaCards based summary : Uterus Leiomyosarcoma, also known as leiomyosarcoma of the corpus uteri, is related to leiomyosarcoma. An important gene associated with Uterus Leiomyosarcoma is MKI67 (Marker Of Proliferation Ki-67). The drugs Doxorubicin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and the smooth muscle of the uterus.

Related Diseases for Uterus Leiomyosarcoma

Diseases related to Uterus Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 leiomyosarcoma 10.0

Symptoms & Phenotypes for Uterus Leiomyosarcoma

Drugs & Therapeutics for Uterus Leiomyosarcoma

Drugs for Uterus Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved Phase 3 51-75-2 4033
5
Lenograstim Approved Phase 3,Phase 2 135968-09-1
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Bevacizumab Approved, Investigational Phase 3 216974-75-3
8
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
12
Doxil Approved June 1999 Phase 3,Phase 2 31703
13 Alkylating Agents Phase 3,Phase 2
14 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
15 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
16 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 2
21 Antibiotics, Antitubercular Phase 3,Phase 2
22 Antimetabolites, Antineoplastic Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2
25 Antiviral Agents Phase 3,Phase 2
26 pancreatic polypeptide Phase 3
27 Analgesics Phase 3
28 Mitogens Phase 3,Phase 2
29 Adjuvants, Anesthesia Phase 3
30 Adjuvants, Immunologic Phase 3,Phase 2
31 Narcotics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Peripheral Nervous System Agents Phase 3
37 Endothelial Growth Factors Phase 3,Phase 2
38 Immunoglobulin G Phase 3
39 Immunoglobulins Phase 3,Phase 2
40 Antibodies, Monoclonal Phase 3,Phase 2
41 Isophosphamide mustard Phase 3,Phase 2
42 Liver Extracts Phase 3,Phase 1
43 Antibodies Phase 3,Phase 2
44 Central Nervous System Depressants Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46
Serotonin Phase 3 50-67-9 5202
47 Serotonin Agents Phase 3
48 Serotonin Antagonists Phase 3
49 Gastrointestinal Agents Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 60)
id Name Status NCT ID Phase
1 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Completed NCT01012297 Phase 3
2 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Recruiting NCT01533207 Phase 3
8 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
10 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
11 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2
12 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
13 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
14 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2
15 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2
16 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2
17 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2
18 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2
19 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2
20 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2
21 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2
22 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
24 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2
25 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
28 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2
29 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
33 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
34 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
36 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2
37 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2
38 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
39 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
40 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Recruiting NCT02428192 Phase 2
41 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
42 Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Recruiting NCT01442662 Phase 2
43 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Active, not recruiting NCT01220609 Phase 2
44 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Active, not recruiting NCT02249702 Phase 2
45 Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Active, not recruiting NCT00414076 Phase 2
46 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
47 Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003316 Phase 2
48 Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT00003054 Phase 2
49 Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus Terminated NCT00033644 Phase 2
50 Pazopanib for Treating Uterine Leiomyosarcoma Withdrawn NCT02378142 Phase 2

Search NIH Clinical Center for Uterus Leiomyosarcoma

Genetic Tests for Uterus Leiomyosarcoma

Anatomical Context for Uterus Leiomyosarcoma

MalaCards organs/tissues related to Uterus Leiomyosarcoma:

39
Uterus, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Uterus Leiomyosarcoma:

18
The Smooth Muscle Of The Uterus

Publications for Uterus Leiomyosarcoma

Variations for Uterus Leiomyosarcoma

Expression for Uterus Leiomyosarcoma

Search GEO for disease gene expression data for Uterus Leiomyosarcoma.

Pathways for Uterus Leiomyosarcoma

GO Terms for Uterus Leiomyosarcoma

Sources for Uterus Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....